Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP209075.RACJIYDL6PpYqJdVjKH1naRcVR3Uo_r22KNDxxHsnqNwo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP209075.RACJIYDL6PpYqJdVjKH1naRcVR3Uo_r22KNDxxHsnqNwo130_assertion type Assertion NP209075.RACJIYDL6PpYqJdVjKH1naRcVR3Uo_r22KNDxxHsnqNwo130_head.
- NP209075.RACJIYDL6PpYqJdVjKH1naRcVR3Uo_r22KNDxxHsnqNwo130_assertion description "[One of the major breakthroughs both in the lamin field and for this syndrome is that many of the cellular defects observed in HGPS patient cells and model systems can be restored after treatment with a class of compounds known as FTIs (farnesyltransferase inhibitors).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP209075.RACJIYDL6PpYqJdVjKH1naRcVR3Uo_r22KNDxxHsnqNwo130_provenance.
- NP209075.RACJIYDL6PpYqJdVjKH1naRcVR3Uo_r22KNDxxHsnqNwo130_assertion evidence source_evidence_literature NP209075.RACJIYDL6PpYqJdVjKH1naRcVR3Uo_r22KNDxxHsnqNwo130_provenance.
- NP209075.RACJIYDL6PpYqJdVjKH1naRcVR3Uo_r22KNDxxHsnqNwo130_assertion SIO_000772 20074076 NP209075.RACJIYDL6PpYqJdVjKH1naRcVR3Uo_r22KNDxxHsnqNwo130_provenance.
- NP209075.RACJIYDL6PpYqJdVjKH1naRcVR3Uo_r22KNDxxHsnqNwo130_assertion wasDerivedFrom befree-20140225 NP209075.RACJIYDL6PpYqJdVjKH1naRcVR3Uo_r22KNDxxHsnqNwo130_provenance.
- NP209075.RACJIYDL6PpYqJdVjKH1naRcVR3Uo_r22KNDxxHsnqNwo130_assertion wasGeneratedBy ECO_0000203 NP209075.RACJIYDL6PpYqJdVjKH1naRcVR3Uo_r22KNDxxHsnqNwo130_provenance.